CTLA4 and melanoma: These therapies have prolonged progression-free and overall survival in melanoma patients, with a median overall survival (OS) of 49% and a melanoma-specific survival of 56% at 6.5 years for patients treated with a combination of CTLA-4 and PD-1 inhibition [4].